Centogene NV
NASDAQ:CNTG
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
DE |
Centogene NV
NASDAQ:CNTG
|
10.9m USD | -0.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 12.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 20.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 31.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.5B USD | 22.7 | ||
AU |
CSL Ltd
ASX:CSL
|
135.2B AUD | 33.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84B USD | 10.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
48.2B USD | -16.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 19.9 | ||
KR |
Celltrion Inc
KRX:068270
|
39.5T KRW | 73.6 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.